Clinical trial · Observational
Optimizing Fall-risk Prediction in Older Adults With Cancer
NCT02912273CI-TRIAL-00047640completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To establish the optimal strategy of fall-risk assessment to predict falls in older adults receiving cancer therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Baseline Healthcare Provider Assessment | Other | — | UNRESOLVED |
| Baseline Participant Assessment | Other | — | UNRESOLVED |
| End-of-study Healthcare Provider Assessment | Other | — | UNRESOLVED |
| End-of-study Participant Assessment | Other | — | UNRESOLVED |
| Follow-up Healthcare Provider Assessment | Other | — | UNRESOLVED |
| Follow-up Participant Assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Fall Risk Assessment Group
- description
- -Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
- interventionNames
- Other: Baseline Participant Assessment
- Other: Baseline Healthcare Provider Assessment
- Other: Follow-up Participant Assessment
- Other: Follow-up Healthcare Provider Assessment
- Other: End-of-study Participant Assessment
- Other: End-of-study Healthcare Provider Assessment
Primary outcomes (1)
- measure
- Number of falls
- timeFrame
- Up to 6 months
- description
- -The Prevention of Falls Network Europe (PROFANE) Consensus Group guidelines will be used
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥65 * Receiving systemic cancer therapy, including conventional chemotherapy, novel/targeted agents or hormonal agents (e.g. anti-estrogen or anti-androgen) OR will begin systemic therapy within the next 4 weeks. * Estimated life expectancy \>1 year * Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites * Able to understand and willing to sign an IRB-approved written informed consent document Exclusion Criteria: * Unable to read and understand English
References
Publications (0)
Data not yet available
No reference posted for this study.